Cargando…
Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years
OBJECTIVES: Drug treatment for children with epilepsy should, ideally, be governed by evidence from adequate and well‐controlled clinical studies. However, these studies are difficult to conduct, and so direct evidence supporting the informed use of specific drugs is often lacking. The Research Roun...
Autores principales: | French, Jacqueline A., Cleary, Elena, Dlugos, Dennis, Farfel, Gail, Farrell, Kathleen, Gidal, Barry, Grzeskowiak, Caitlin L., Gurrell, Rachel, Harden, Cynthia, Stalvey, Tracy J., Tsai, Julia, Wirrell, Elaine C., Blum, David, Fountain, Nathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804346/ https://www.ncbi.nlm.nih.gov/pubmed/35835554 http://dx.doi.org/10.1111/epi.17366 |
Ejemplares similares
-
Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE
por: Millichap, John J., et al.
Publicado: (2021) -
Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs
por: Patsalos, Philip N., et al.
Publicado: (2020) -
Patient considerations in the management of focal seizures in children and adolescents
por: Kenney, Daniel, et al.
Publicado: (2014) -
Pronounced antiseizure activity of the subtype‐selective GABA(A)
positive allosteric modulator darigabat in a mouse model of drug‐resistant focal epilepsy
por: Gurrell, Rachel, et al.
Publicado: (2022) -
Teratogenicity and Antiseizure Medications
por: Meador, Kimford
Publicado: (2020)